Allergy

Papers
(The H4-Index of Allergy is 63. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Risk factors for severe and critically ill COVID‐19 patients: A review864
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19781
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria382
Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors381
COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China300
Type 2 immunity in the skin and lungs290
Eleven faces of coronavirus disease 2019236
EAACI guidelines: Anaphylaxis (2021 update)191
The effects of climate change on respiratory allergy and asthma induced by pollen and mold allergens181
Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper169
EAACI Biologicals Guidelines—Recommendations for severe asthma154
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update150
Epithelial cell dysfunction, a major driver of asthma development146
Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented?142
Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID‐19 patients134
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease130
Immunology of COVID‐19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)125
Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status125
Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma124
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice124
The role of peripheral blood eosinophil counts in COVID‐19 patients113
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation110
Abstracts Poster110
Is asthma protective against COVID‐19?108
Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID‐19105
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?100
Spotlight on microRNAs in allergy and asthma96
The role of allergen‐specific IgE, IgG and IgA in allergic disease95
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement95
Advances and recent developments in asthma in 202094
Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic?94
Interleukin‐31: The “itchy” cytokine in inflammation and therapy92
Antibody dynamics to SARS‐CoV‐2 in asymptomatic COVID‐19 infections90
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches88
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines88
Advances and highlights in allergic rhinitis88
Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI‐mediated signaling85
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐284
Advances and highlights in biomarkers of allergic diseases84
Asthma and COVID‐19: Is asthma a risk factor for severe outcomes?83
Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation81
Is BCG vaccination affecting the spread and severity of COVID‐19?80
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biol80
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines77
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐1975
Advances and novel developments in allergic rhinitis74
A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema73
The global burden of illness of peanut allergy: A comprehensive literature review72
EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma71
Advances and highlights in asthma in 202171
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement71
Regulatory B cells, A to Z70
Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement70
Distinct characteristics of COVID‐19 patients with initial rRT‐PCR‐positive and rRT‐PCR‐negative results for SARS‐CoV‐269
Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy68
The ingenious mast cell: Contemporary insights into mast cell behavior and function68
Butyrate as a bioactive human milk protective component against food allergy67
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations66
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives66
Predictors of treatment response in chronic spontaneous urticaria65
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis65
Biologics and airway remodeling in severe asthma63
Past, present, and future of allergen immunotherapy vaccines63
Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders63
0.10762977600098